uniQure Announces Financial Results for Second Quarter 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Chardan Capital Trims PT on uniQure (QURE) to $35; Notes Uncertainty of Glybera in the U.S.
August 27, 2015 12:02 PM EDTChardan Capital trims its price target on uniQure N.V. (Nasdaq: QURE) from $40 to $35 and maintains a Buy rating following Q2 results and update issued earlier.
Analyst Gbola Amusa noted that the lowered price target stems from (1) uncertainty for Glybera... More
uniQure (QURE) Reports Q2 Loss of EUR0.51/Share
August 27, 2015 6:07 AM EDTuniQure (NASDAQ: QURE) reported Q2 EPS of (EUR0.51), versus (EUR0.87) reported last year. Revenue for the quarter came in at EUR1.04 million, versus EUR1.62 million reported last year.
Pipeline Updates
Hemophilia B: Dosing is underway in the Phase I/II study of AMT-060 in hemophilia B and the Company anticipates... More